THE ONLY INDEX THAT OBJECTIVELY ASSESSES THE DIGITIZATION OF PHARMACEUTICAL COMPANIES

WHAT IS THE INDEX?

An objective assessment of the investments being made in innovation to enhance the digitization of pharma. This both encourages innovation and enables companies to benchmark their innovation activities via an objective external source.

INDEX COMPONENTS

The CNS Summit Innovation Index assesses innovation and ranks companies across three dimensions: technology advancement, trial optimization and innovative partnerships. It also factors in how the use of inventions generate tangible value that did not previously exist.

IF YOU ARE INTERESTED IN THE DIGITAL TRANSFORMATION OF PHARMA, YOU NEED TO FOLLOW THE CNS SUMMIT INNOVATION INDEX AND JOIN THE COMMUNITY. WE ARE SHAPING THE FUTURE.

Metrics are calculated using publicly available information.

Developed in collaboration with

[Image of a diagram showing the index components: Technology Advancement, Trial Optimization, Innovative Partnerships, Patient Experience, Connectivity Across Devices, Novel Use of Analytics, Targeted Patient Recruitment, Optimization Through Digitization, Outcomes Centered Care, Investment in Startups & Incubators, Outcomes Centered Care.]